Serum sclerostin was found higher in postmenopausal than premenopausal women, and the administration of selective estrogen receptor modulators (SERMs) for the treatment of osteoporosis reduced serum sclerostin levels [42]. This evidence concerns the gene SOST and osteoporosis.